ATE446772T1 - Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti- angiogenes protein oder teile davon kodiert, enthalten - Google Patents

Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti- angiogenes protein oder teile davon kodiert, enthalten

Info

Publication number
ATE446772T1
ATE446772T1 AT02727017T AT02727017T ATE446772T1 AT E446772 T1 ATE446772 T1 AT E446772T1 AT 02727017 T AT02727017 T AT 02727017T AT 02727017 T AT02727017 T AT 02727017T AT E446772 T1 ATE446772 T1 AT E446772T1
Authority
AT
Austria
Prior art keywords
compositions
gene therapy
rheumatoid arthritis
parts
gene
Prior art date
Application number
AT02727017T
Other languages
English (en)
Inventor
Jong-Mook Kim
Seong-Hyun Ho
Eun-Jin Park
Sun-Young Kim
Original Assignee
Viromed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Ltd filed Critical Viromed Ltd
Application granted granted Critical
Publication of ATE446772T1 publication Critical patent/ATE446772T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02727017T 2001-01-05 2002-01-03 Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti- angiogenes protein oder teile davon kodiert, enthalten ATE446772T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20010000691 2001-01-05
PCT/KR2002/000001 WO2002053191A1 (en) 2001-01-05 2002-01-03 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof

Publications (1)

Publication Number Publication Date
ATE446772T1 true ATE446772T1 (de) 2009-11-15

Family

ID=36932148

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727017T ATE446772T1 (de) 2001-01-05 2002-01-03 Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti- angiogenes protein oder teile davon kodiert, enthalten

Country Status (8)

Country Link
US (3) US7175840B2 (de)
EP (1) EP1371377B1 (de)
JP (1) JP2004517117A (de)
KR (1) KR100495316B1 (de)
CN (1) CN1455682A (de)
AT (1) ATE446772T1 (de)
DE (1) DE60234163D1 (de)
WO (1) WO2002053191A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
JP5823663B2 (ja) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド ミスフォールドｓｏｄ１媒介疾患を処置および検出するための方法および組成物
MX2009011523A (es) 2007-04-27 2009-11-09 Dow Global Technologies Inc Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas.
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009038771A2 (en) * 2007-09-19 2009-03-26 Massachusetts Institute Of Technology Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers
JP2009091339A (ja) * 2007-10-12 2009-04-30 Seikagaku Kogyo Co Ltd 関節リウマチの処置剤
WO2009116529A1 (ja) 2008-03-18 2009-09-24 国立大学法人 北海道大学 ポリペプチドおよび当該ポリペプチドを含む医薬組成物
JP5972163B2 (ja) * 2009-05-13 2016-08-17 メディポスト カンパニー リミテッド 幹細胞の細胞活性と関連したｔｓｐ−１、ｔｓｐ−２、ｉｌ−１７ｂｒ及びｈｂ−ｅｇｆ並びにそれらの用途
US9040298B2 (en) 2009-05-29 2015-05-26 Medipost Co., Ltd. Method of selecting stem cells having high chondrogenic differentiation capability
KR20150139569A (ko) * 2013-04-02 2015-12-11 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 혈관형성의 유도 및 조절을 위한 조성물 및 방법 및 혈관형성 조절 인자를 확인하기 위한 방법 및 분석법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
US6156304A (en) * 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
JPH064684A (ja) 1992-06-22 1994-01-14 Fujitsu Ltd データ収集装置および方法
WO1994007524A1 (en) * 1992-10-02 1994-04-14 California Pacific Medical Center Research Institute Method of treatment of arthritis with platelet factor 4
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
CA2188813C (en) 1994-04-26 2010-08-03 Michael S. O'reilly Angiostatin protein, nucleic acids encoding the same and methods of detection
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
KR19990066981A (ko) 1995-10-23 1999-08-16 윌리엄 뉴우 치료용 맥관형성억제 조성물 및 방법
KR100217586B1 (ko) 1995-12-21 1999-09-01 정몽규 자동차의 동적 폐력 측정 장치
US6190907B1 (en) * 1996-09-21 2001-02-20 Viromedica Pacific Limited Retroviral vectors for gene therapy
AU730817B2 (en) 1997-05-15 2001-03-15 Shunichi Shiozawa A gene causative of rheumatoid arthritis, method for diagnosing rheumatoid arthritis, and method for identifying causative factors of rheumatoid arthritis
EP1086129A1 (de) 1998-06-17 2001-03-28 Beth Israel Deaconess Medical Center Anti-angiogenische proteine und deren verwendungen
KR20000006334A (ko) 1998-06-26 2000-01-25 이선경 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
US20020115202A1 (en) * 1999-08-13 2002-08-22 Paul Hallenbeck Adenoviral vectors including dna sequences encoding angiogenic inhibitors
JP3726005B2 (ja) 2000-03-09 2005-12-14 株式会社 日立インダストリイズ 多段遠心圧縮機
JP2001256030A (ja) 2000-03-14 2001-09-21 Seiko Epson Corp 印刷システム、印刷制御装置及びプログラム記録媒体
AU8727401A (en) 2000-03-29 2001-10-08 Beth Israel Hospital Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
US6803211B2 (en) 2000-08-25 2004-10-12 Pfizer Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
EP1197550A3 (de) 2000-08-25 2002-11-20 Pfizer Products Inc. Methoden und Zusammensetzungen zur Diagnose unde Behandlung von Krankheiten an denen Angiogenese beteiligt ist
WO2002045737A2 (en) 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7

Also Published As

Publication number Publication date
CN1455682A (zh) 2003-11-12
EP1371377A4 (de) 2006-01-18
DE60234163D1 (de) 2009-12-10
WO2002053191A1 (en) 2002-07-11
EP1371377A1 (de) 2003-12-17
US20060193833A1 (en) 2006-08-31
US20050277603A1 (en) 2005-12-15
JP2004517117A (ja) 2004-06-10
KR100495316B1 (ko) 2005-06-14
EP1371377B1 (de) 2009-10-28
US7175840B2 (en) 2007-02-13
KR20020057824A (ko) 2002-07-12
US20060198826A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
ATE446772T1 (de) Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti- angiogenes protein oder teile davon kodiert, enthalten
ATE265529T1 (de) Bmp-10 zusammensetzungen
DK0753053T3 (da) Alfavirus-cDNA-vektorer
ES8304200A1 (es) "un procedimiento para formar dna doble filamentado".
EA200400312A1 (ru) АНТАГОНИСТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFSF13b ЧЕЛОВЕКА
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE336240T1 (de) Therapeutische verwendung von stickstoffmonoxydinhibitoren
ATE253631T1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
ATE302015T1 (de) Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon
DK55086D0 (da) Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektorertil brug ved fremgangsmaaden
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
ATE302274T1 (de) Methoden zur bestimmung von komponenten zur modulation des körpergewichts
DE69332978D1 (de) Methode zur inhibition der replikation von hyperproliferativen zellen
EA200001124A1 (ru) Способ генной терапии
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE60335473D1 (de) Primäre kultivierte adipozyten zur gentherapie
DE60108094D1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
EP1429650A4 (de) Alternativ gesplicter zirkulierender gewebefaktor
ES2167322T3 (es) Proteina de tipo cadherinico relacionada con los huesos y procedimiento para su preparacion.
WO2004030630A3 (en) Focal calcium channel modulation
ATE162853T1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
ATE315935T1 (de) Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties